XUANZHUBIO-B's stock price soared 12.96% during the morning trading session, following the release of the company's annual financial results for the fiscal year ending December 31, 2025.

The surge is attributed to significantly improved financial performance. The company reported a 72.03% year-on-year increase in revenue to RMB51.772 million and a 102.33% surge in gross profit to RMB33.369 million. Furthermore, the loss attributable to owners of the parent narrowed by 55.88% to RMB246 million.

Investor confidence was also bolstered by positive updates on the commercialization of its key drugs. The group has made substantial progress in building sales networks and teams for its digestive system disease and oncology products, expanding its reach to over 2,000 medical institutions nationwide.